Cancer Antigen 15-3 (CA15-3) ELISA Kit

  • Created on the 11 May, 2017.


Cancer antigen 15-3 (also called carcinoma antigen 15-3, CA15-3), is a vital tumor marker which is often used to monitor how well a patient responds to breast cancer treatment and to follow-up on breast cancer recurrence. CA15-3 is derived from MUC1 gene and the associated CA 27-29 are different epitopes that can be present on the same protein antigen product of MUC1 gene. One of the primary uses CA 15-3 is to monitor therapy in patients having metastatic disease, this can be present at the initial period of diagnosis or can occur during any time after the primary therapy. There are a large number of findings which indicate that up to 70% of patients with metastases will respond positively to any systemic treatment using endocrine therapy or cytotoxic drugs, this means that early detection is vital in order to manage patients for recurrence. Furthermore, CA 15-3 can be useful for postoperative surveillance of asymptomatic women that have undergone under gone invasive breast cancer surgery. Although, it has been preferentially linked with breast cancer, this is not tissue specific and there have been findings to suggest elevated levels are also present in other different varieties such as colon adenocarcinoma and ovarian cancer.


Human CA 15-3 ELISA kit is a procedure for determining in vitro quantitative levels of cancer antigen 15-3 (carcinoma antigen 15-3 and CA15-3) in human serum and plasma samples. This assay has a minimum sensitivity limit of 0.5 U/ml.


The minimum detection sensitivity level of human CA-15-3 (carcinoma antigen 15-3) using this human cancer antigen 15-3 ELISA kit was 0.5 U/ml. The dynamic assay range for this kit is 25.0 – 200.0 U/ml.


  1. CA 15-3: uses and limitation as a biomarker for breast cancer. Clin Chim Acta. (2010) 411 (23-24): 1869-74. Review. Duffy M.J., et al.
  2. Biomarkers in Breast Cancer: Where Are We and Where Are We Going? Adv Clin Chem. (2015) 71: 1-23. Review. Duffy M.J., et al.
  3. Analytical requirements and standardization of CA 15-3. Scand J Clin Lab Invest Suppl. (1995) 221: 102-4. Review. van Dalen A.
  4. MUC1 (CD227): a multi-tasked molecule. Cell Mol Life Sci. (2015) 72 (23): 4475-500. Review. Apostolopoulos V., et al.
  5. CA 15-3 and bone scintigraphy in the follow-up of breast cancer. Int J Biol Markers. (1997) 12 (4): 154-7. Review. Younsi N., et al.


  • Full Name: Cancer Antigen 15-3 (CA15-3) ELISA Kit
  • Reactivity: Human
  • Sample Type: Plasma, Serum
  • Sensitivity: 0.5 U/ml



Your secretory IgA ELISA kit gave good results and I was also really impressed with how quickly we received it.

L. Johnston
PhD Student / University of Glasgow

It is refreshing to know that you have a technical team that is very knowledgeable. I have already recommended your company to other researchers in our department.

Dr. P. Anderson
Lecturer / University College London (UCL)

I am a first time user and found that your instruction manual was very easy to follow. The insulin ELISA kit performed well and I was happy with the results that were generated.

J. Thomas
Senior Technician / Addenbrooke’s Hospital

I carried out a pilot study comparing the performance of many ELISA kits from different suppliers and found your kits to be one of the better performers. We observed good linearity and tight replicates.

Dr. C. Davies
Lead Scientists / AstraZeneca

You are my first point of contact when I am looking to purchase ELISA kits. You have such an easy and simple system, yet it is very effective.

A. Shaw
Purchasing / University of Oxford